$0.87-0.06 (-6.70%)
Lucyd, Inc develops and sells smart eyewear in North America.
Lucyd, Inc in the Healthcare sector is trading at $0.87 with a market capitalization of $6M. The stock is currently near its 52-week low of $0.65, remaining 18.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $773,561β | $959,810β | $668,128β | $579,230β | $454,501 |
| Gross Profit | $175,445β | $114,746β | $244,837β | -$12,665β | $220,533 |
| Operating Income | -$2.37Mβ | -$2.50Mβ | -$1.92Mβ | -$2.17Mβ | -$1.90M |
| Net Income | -$2.31Mβ | -$1.87Mβ | -$1.84Mβ | -$2.11Mβ | -$1.78M |
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescript...

Innovative Eyewear, Inc. (NASDAQ:LUCY) is expanding Lucyd Armor into more than 150 stores operated by one of the largest big box retailers in the United States, giving the smart eyewear company a potentially significant new physical retail channel.
The software update expands Lucyd smart glasses with Claude AI while introducing a multi-model platform that also supports ChatGPT. Key Investor TakeawaysInnovative Eyewear (NASDAQ:LUCY) is launching a Claude AI integration for all Lucyd smart eyewear models next week.
Monte Rosa Therapeutics (GLUE) said Wednesday early trial results of its drug candidate, MRT-8102, s
HIVE Digital Technologies Ltd. 18,030,962 3.2599